BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Tumor-Directed and Alloreactive T-Cells Synergize in the Rejection
  of Mouse Prostate Cancer - joint IBI & ISREC seminar
DTSTART:20130611T110000
DTEND:20130611T120000
DTSTAMP:20260925T073441Z
UID:751901ece3b73fc5913192243d2884f356864bea388c31888dc6ae02
CATEGORIES:Conferences - Seminars
DESCRIPTION:Anna Mondino\, PhD\, San Raffaele Scientific Institute\, Milan
  (I)\nBio: 1988 Master in Biological Sciences\, University of Turin\, Ital
 y\n1992 Ph.D.\, Molecular Oncology\, University of Turin\, Italy\nResearch
  and professional experience:\n   1986-1988 - Undergraduate student\n 
   1988-1989 - Research Fellow\, AIRC\n   1989-1991 - Ph.D. student in M
 olecular Oncology\n       Department of Biomedical Science and Oncolog
 y\, Turin\, Italy\n    1991-1992 - Ph.D. student in Molecular Oncology\
 n        Dr. Schlessinger' s lab\, Department of Pharmacology\n   
      New York University\, Medical Center\, New York\, USA\n    1993-
 Feb. 1998 - Postdoctoral Associate\n        Department of Microbiol
 ogy\n        University of Minnesota\, Medical School\, Minneapolis\
 , MN\, USA\n    April 1998-1999 - Research Associate\n       Depart
 ment of Molecular Pathology and Medicine\n       DIBIT/ H. S. Raffael
 e\, Milan\, Italy\n    Since January 2000 - Principal Investigator\n 
       Lymphocyte Activation Unit\n       Cancer Immuno-therapy an
 d Gene Therapy Program\n       Department of Immunology and Infectiou
 s Diseases\n       DIBIT/ San Raffaele Scientific Institute\, Milan\
 , Italy\nWe are interested in the cellular and molecular mechanisms dictat
 ing protective immunity against malignant tumors. We have adopted the Tran
 sgenic Adenocarcinoma of the Mouse Prostate cancer (TRAMP) model\, which c
 losely recapitulate prostate cancer occurrence and progression in humans\,
  to design\, test and validate innovative immunotherapeutic strategies sui
 table of clinical translation. Results describing the therapeutic efficacy
  obtained by combining tumor and alloreactive T cells in the contest of he
 matopoietic cell allotransplantation and of adoptive T cell therapy with a
 utologous TCR gene engineered T cells will be discussed.
LOCATION:SV1717a http://map.epfl.ch/?room=sv1717a
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR